GlassScriptPhysician profile
Jake Gurland
NPI 1174028435
$2,214.55
in general payments reported to CMS, 2019-2025
33 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7.20 · 2022: $128 · 2023: $184 · 2024: $658 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $400.66 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $305.41 | 2023-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $192.13 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $154.70 | 2022-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $148.51 | 2022-2025 | |
| Viiv Healthcare Company | $137.18 | 2024-2025 | Apretude |
| Gilead Sciences, INC. | $101.24 | 2024-2025 | |
| Exact Sciences Corporation | $96.85 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Corcept Therapeutics | $88.27 | 2025 | Korlym |
| Mallinckrodt Hospital Products INC. | $78.35 | 2025 | Acthar |
| Amgen INC. | $41.48 | 2025 | Repatha |
| Dexcom, INC. | $40.92 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $37.04 | 2025 | Recorlev |
| Antares Pharma, INC. | $33.98 | 2024 | Xyosted |
| Nevro Corp. | $33.23 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $29.34 | 2024 | Minimed 780g |
| Abbvie INC. | $28.33 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $24.55 | 2022 | |
| Biotronik Nro, INC. | $22.45 | 2025 | Prospera |
| Bayer Healthcare Pharmaceuticals INC. | $22.39 | 2025 | |
| Ani Pharmaceuticals, INC. | $21.97 | 2025 | Purified Cortrophin Gel |
| Biotissue Holdings INC. | $21.70 | 2022 | |
| Ardelyx, INC. | $19.18 | 2025 | Ibsrela |
| Sumitomo Pharma America, INC. | $18.52 | 2025 | Gemtesa |
| Currax Pharmaceuticals LLC | $17.21 | 2025 | Contrave |
| Axsome Therapeutics, INC. | $15.51 | 2025 | Symbravo |
| Esperion Therapeutics, INC. | $15.12 | 2024 | Nexletol |
| Paratek Pharmaceuticals, INC. | $14.39 | 2024 | Nuzyra |
| Smith+Nephew, INC. | $13.18 | 2024 | Collagenase Santyl |
| Supernus Pharmaceuticals, INC. | $12.93 | 2023 | Qelbree |
| Genentech, INC. | $10.78 | 2022 | |
| Genentech USA, INC. | $9.85 | 2022 | |
| Travere Therapeutics, INC. | $7.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Gurland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.